IFNA1 and lymphoma: The value of combining IFN-DC with other agents has been extensively demonstrated by our recent therapeutic approach with IFN-DC-based lymphoma vaccine and the immunomodulatory drug lenalidomide in the treatment of xenochimeric mice bearing established human lymphoma, resulting in a massive regression of tumor masses and long-lasting inhibition of tumor regrowth after treatment discontinuation, over the single treatments [65].